A REVIEW OF TRASTUZUMAB SEQUENCE

Probably the most under-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) reported the loss of PTEN was noticed in 36% of HER2-optimistic Main breast tumor specimens from patients with stage IV disorder. Moreover, In addition they showed that individuals with PTEN-deficient tumors experienced remar